)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Talisman Metals
Talisman Metals (TLM) investor relations material
Talisman Metals H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary30 Sep, 2026
Executive summary
Completed acquisition of Tadeen International Limited, gaining a portfolio of Moroccan copper and silver exploration licenses.
Entered binding agreement to acquire Tirzzit Copper Project in Morocco, with regulatory transfer pending.
Ongoing exploration at Fougnar and Tirzzit projects throughout the period.
Completed a post-period share placement raising £501,800 in August 2026.
Financial highlights
Reported a loss for the period of €1.203 million, compared to €0.765 million loss in H1 2025.
Total comprehensive loss for the period was €2.477 million, up from €0.796 million in H1 2025.
Cash and cash equivalents at 30 June 2026 were €1.310 million, down from €2.005 million at year-end 2025.
No long-term debt or contingent future payments related to assets and projects.
Outlook and guidance
Management anticipates completion of the Tirzzit Copper Project regulatory transfer later in 2026.
Directors remain confident in the company's ability to raise future funding through equity placements.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Talisman Metals
- Developing copper projects in Morocco with strong leadership and promising exploration results.TLM
Corporate presentation - Strategic pivot to copper exploration, €1.7m profit, and AIM readmission amid funding risks.TLMH2 2025
- Negative clinical results drove a €5.13m loss and a shift to cost control and new strategy.TLMH2 2023
- Exited biopharma after failed trials, pivoting to minerals exploration with improved 2024 results.TLMH2 2024
- H1 2025 saw a €1.24M loss, discontinued biopharma, and a shift to new business strategies.TLMH1 2025
- Losses narrowed and cash reserves remain, as strategic alternatives are actively pursued.TLMH1 2024
Talisman Metals
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Ovoca Bio plc is a clinical-stage biopharmaceutical company focusing on women's health. The company is actively involved in developing novel therapeutic products, particularly targeting female sexual dysfunction. Its lead candidate, a treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women, is under clinical development. Ovoca Bio's research and development efforts are geared towards addressing unmet medical needs in this area. The company is headquartered in Dublin, Ireland, and its shares are listed on the Euronext Dublin.